N-Acetylglucosamine (GlcNAc)

DRUG2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Johns Hopkins University

Conditions

Crohns DiseasePGM3

Phase 1

Immunologic Effects of Supplemental Monosaccharide and Nucleoside Derivatives in Patients With Inherited Disorders of Glycosylation

TerminatedNCT02511041

National Institute of Allergy and Infectious Diseases (NIAID)PGM3

Start: 2015-06-30End: 2017-01-24Updated: 2017-07-02

Phase 2

Oral N-acetylglucosamine in Crohn's Disease

Not yet recruitingNCT07225998

Johns Hopkins UniversityCrohns Disease

Start: 2026-11-01End: 2028-12-31Target: 40Updated: 2026-09-11